Screener
Aquestive Therapeutics, Inc. AQST Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Co-development and research fees | $582K+54.0% | $258K-38.3% | $181K-33.9% | $302K-38.6% | $378K-50.0% | |
| License and royalty revenue (a) | $1.33M+58.0% | $5.4M+583% | $852K+2.5% | $1.04M-52.0% | $839K-92.5% | |
| Manufacture and supply revenue | $11.91M+24.3% | $8.79M+22.2% | $11.98M+12.4% | $11.47M+7.5% | $9.58M+18.0% | |
| Proprietary product revenue, net | $0+100% | $0-100% | $0-100% | $0-100% | -$797K— | |
| Revenue by Geography | ||||||
| Ex-United States | $2.83M-44.7% | $1.2M-65.9% | $3.63M+43.0% | $2.68M-10.9% | $5.11M-51.1% | |
| United States | $10.99M+125% | $13.25M+155% | $9.39M+0.6% | $10.12M-3.8% | $4.89M-49.3% |
FAQ
- How does Aquestive Therapeutics, Inc. break its business down?
- Aquestive Therapeutics, Inc. (AQST) reports revenue by product across 4 parts — Co-development and research fees, License and royalty revenue (a), Manufacture and supply revenue and Proprietary product revenue, net. Each is extracted from the segment footnotes and tracked over time.
- Where does Aquestive Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Aquestive Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
